Compare Cassava Sciences Inc (FLNA) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Nebius Group NV — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Nebius Group NV trades at $174.1 (market cap $50.66B). The key difference: Nebius Group NV is far larger — about 953.3× Cassava Sciences Inc's market cap, and Nebius Group NV is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | NBIS | |
|---|---|---|
Market Cap | $53.14M | $50.66B |
Sector | Health | Technology |
52-Week High | $4.64 | $286.69 |
52-Week Low | $1.09 | $50.40 |
Enterprise Value | -$33.43M | $50.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
NBIS trades at $171.75, down 11.46% over 24 hours amid broader tech sector volatility. The stock shows bearish technical signals with support at $174 and resistance at $197. Fundamentally, the company reported Q1 2026 EPS of -$0.23, beating expectations, while Q4 2025 missed. Revenue grew to $529.8M in 2025 with a strong net income margin of 93.09%. Recent news highlights a $1B compute deal with Reflection AI and positive analyst coverage despite recent price pressure.
Outlook remains positive with 87.5% analyst buy ratings and a $248 consensus price target, implying 44% upside. Key risks include competitive pressures from Meta's cloud capacity and high valuation multiples (P/E 77). The company's expansion into AI infrastructure and partnerships supports long-term growth, but investors should monitor execution on capacity build-out and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
